A Prospective Virtual Study to Evaluate the Longevity of IgG Antibodies in Individuals Exposed to COVID-19


The primary objective of this study is to describe the longevity of IgG against SARS-CoV-2 infection or vaccination.

Full Title of Study: “A Prospective Cohort Study of Immunoglobulin G (IgG) Dynamics Against SARS-Co”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Other
  • Study Primary Completion Date: May 31, 2022

Detailed Description

This virtual clinical study will use a prospective design, to evaluate longevity and seroprevalence of IgG against SARS-CoV-2 in approximately 800 patients as measured by Dried Blood Spots via fingerstick using the Everlywell COVID-19 Antibody Test Home Collection Kit. Participants will be followed up to 9 months at 1, 3, 6 and 9 months after enrollment.


  • Other: SARS-CoV-2
    • Observational

Arms, Groups and Cohorts

  • Unvaccinated SARS-CoV-2 positive
    • Participants who have tested positive for SARS-CoV-2, both with and without symptoms, who have not been vaccinated
  • Vaccinated
    • Participants who were vaccinated against SARS-CoV-2

Clinical Trial Outcome Measures

Primary Measures

  • To describe the longevity and seroprevalence of IgG against SARS-CoV-2 in a cohort of individuals exposed to SARS-CoV-2
    • Time Frame: Up to 9 months

Secondary Measures

  • To compare the off-kinetics of IgG positivity against SARS-CoV-2, stratified by age, sex, race, ethnicity, infection symptomaticity, initial viral load
    • Time Frame: Up to 9 months
  • To compare the off-kinetics of IgG positivity against SARS-CoV-2 by natural infection vs vaccination
    • Time Frame: Up to 9 months

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 18 years – Willing to provide informed consent prior to participation. – Cohort 1 (Arm 1) – Positive test results for SARS-CoV-2 virus by an RT-PCR or Antigen test AND not received any COVID-19 vaccine or participated in any COVID-19 vaccine trial – Cohort 2 (Arm 2) – Received the COVID-19 vaccine Exclusion Criteria:

  • Unable or unwilling to provide informed consent – Individuals with known conditions or treatments associated with immune impairment, such as cancer and chemotherapy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Everly Health
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Timothy Bauer, PhD, Principal Investigator, Everly Health

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.